Orbital Therapeutics

📍 Cambridge, United States🗓 Founded 2022👥 75 employees💰 Last funded Mar 2023
Biotechnology Research🌐 orbitaltx.com
Website LinkedIn
Orbital Therapeutics is advancing a new generation of RNA medicines designed to reprogram cells in vivo, treating diseases at their source. This approach offers patients a simpler, safer, and more accessible alternative to today’s complex treatments. Built from day one with a fully integrated platform spanning circular and linear RNA, targeted delivery, and AI-guided design, Orbital is working to develop durable, programmable therapies tailored to the distinct biology of each disease. The company’s lead program, OTX-201, targets autoimmune disease through B cell depletion to reset the immune system. Orbital’s platform is built for expansion into broader autoimmune indications, oncology, next-generation vaccines, and protein therapeutics. Led by a team with deep expertise in RNA science, clinical development, and commercialization, Orbital is united by a shared commitment to reach more patients, in more places, with fewer barriers. Learn more at www.orbitaltx.com.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2022
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Singapore
1
United States
1
Frequently asked questions
Who invested in Orbital Therapeutics?
Orbital Therapeutics has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Orbital Therapeutics last raise funding?
The most recent investment in Orbital Therapeutics recorded on gritt.io was in March 2023.
When was Orbital Therapeutics founded?
Orbital Therapeutics was founded in 2022.
What industry is Orbital Therapeutics in?
Orbital Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Orbital Therapeutics based?
Orbital Therapeutics is headquartered in Cambridge, United States.